Atopische Dermatitis
G-BA action
final resolution
2022-07-07
Evidence-checked summary
The G-BA found a hint of considerable added benefit for Erwachsene mit mittelschwerer bis schwerer atopischer Dermatitis, die für eine kontinuierliche systemische Therapie in Frage kommen. The appropriate comparator was Dupilumab (ggf. in Kombination mit topischen Glukokortikoiden und/oder topischen Calcineurininhibitoren). The G-BA issued a final resolution on 2022-07-07. The official page states that it took effect as follows: 07.07.2022. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
Patient group
Erwachsene mit mittelschwerer bis schwerer atopischer Dermatitis, die für eine kontinuierliche systemische Therapie in Frage kommen
Hint of considerable added benefit
Comparator
Dupilumab (ggf. in Kombination mit topischen Glukokortikoiden und/oder topischen Calcineurininhibitoren)
Official case record
No inferred stages
Consultation record
2022-05-23
80 parsed turns
Oral hearing: Abrocitinib (Atopische Dermatitis)
Official Wortprotokoll · 14 pages
IQWiG comparison
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A22-06
matched
Abrocitinib (atopische Dermatitis) – Nutzenbewertung gemäß § 35a SGB V
Official assessment PDF · 69 pages
G-BA decisions
2022-07-07
final resolution
The G-BA found a hint of considerable added benefit for Erwachsene mit mittelschwerer bis schwerer atopischer Dermatitis, die für eine kontinuierliche systemische Therapie in Frage kommen. The appropriate comparator was Dupilumab (ggf. in Kombination mit topischen Glukokortikoiden und/oder topischen Calcineurininhibitoren). The G-BA issued a final resolution on 2022-07-07. The official page states that it took effect as follows: 07.07.2022. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
2 official documents · 4 cited claims
Official sources